Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surzebiclimab and/or Alcestobart with Tislelizumab in Advanced Solid Tumors
NCT03744468Phase 2Completed
- Sponsor
- BeiGene
- Start
- Nov 2018
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, open-label trial of surzebiclimab and alcestobart in solid tumor, head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC) (5 arms), sponsored by BeiGene. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events and Serious Adverse Events, Maximum Tolerated Dose or Maximum Administered Dose up to 21 days and 2 more. Started Nov 2018; status: completed.
02
Drugs
surzebiclimabalcestobart
03
Conditions
solid tumorhead and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03744468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03744468.